March 3, 2026Open Access

Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial

Key Points

AET adherence was significantly higher at 53.9% for premenopausal women using remote monitoring, compared to 25.0% for those receiving usual care.
The analysis utilized data from a randomized trial with 304 participants, focusing on the distinct adherence challenges faced by menopausal groups.
Findings underscore the potential of app-based monitoring to enhance treatment adherence among younger women battling breast cancer.
Highlighting the lack of adherence benefit for postmenopausal women suggests targeted approaches are necessary for this demographic.

Abstract

Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.

Bookmark

View Full Paper

Cite This Study

Graetz et al. (Wed,) studied this question.

synapsesocial.com/papers/69a75d14c6e9836116a2686d https://doi.org/https://doi.org/10.1038/s41523-026-00900-9

Bookmark

View Full Paper